This study was designed as an observational, prospective, epidemiological screening study. Patients who have been admitted to the center and whose lymphopenia and/or Immunoglobulin E elevation has been detected in at least one examination in their medical history will be included.
In accordance with the relevant legislation, patients are required to accept and sign the Informed Consent Form regarding their participation in the study.
Current data that the physician has already questioned in his daily practice will be collected from patients who have agreed to participate in the study, and a blood sample will be taken from patients on Guthrie paper. This sample will be prepared by taking it from the patient as the physician deems appropriate, dripping it into a special area designated on Guthrie paper and drying it.
The test result will be sent to the researcher by e-mail. In case of formation of new information for each patient, consultation will be provided by the responsible researcher.
Thus, the prevalence of ADA enzyme deficiency disease in patients with lymphopenia will be evaluated. In addition, with this study, it will be scientifically demonstrated whether lymphopenia is a parameter that facilitates early diagnosis of ADA patients.
Who can participate
Age range18 Years – 40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Lymphopenia: The patient has lymphopenia as a result of at least one hemogram,
✓The number of lymphocytes is below 1500/mm3
✓. Immunoglobulin E height: The level of immunoglobulin E is above 120 kU/L.
✓. Two or more new ear infections within a year
✓. Two or more new sinus infections within a year when there is no allergy
✕. Having used drugs that can cause lymphopenia before being included in the study (chemotherapy, cytotoxic drug use, etc.),
✕. The Ministry of Health COVID-19 diagnosis guide (nazofaringeal, nasal orofaringiyal or SARS-CoV-2 RNA PCR test and/or tomographic) as COVID-19, diagnosed and/or persons who had contact with patient recruitment criteria, patients diagnosed in this manner karsilasal PCR tests were negative even after those patients in the study will be taken.
What they're measuring
1
The ratio of adult patients with immunoglobulin E elevation and/or lymphopenia who have an ADA metabolite test above the threshold value
✕. Before being included in the study, it should be noted that other diseases that can cause lymphopenia (hematological diseases, oncological diseases, etc.) have been diagnosed with,
✕. The patient has participated in an interventional clinical trial within the last 30 days,
✕. Failure of the patient himself and/or his legal representative to give their consent to participate in the study,
✕. According to the researcher's opinion, the patient will not be able to properly fulfill the study requirements,